nnDosis offers a web-based tool that personalizes drug dosing for chronic anemia, specifically Erythropoiesis-Stimulating Agents (ESAs). Their Strategic Anemia Advisor (SAA) helps reduce drug utilization while maintaining patient outcomes, charging clients only a share of the realized savings.
Funding
Funding not disclosed
Founders
Product
Problem
Conventional drug dosing for chronic diseases often assumes that patients respond uniformly to medication, leading to suboptimal outcomes and increased risk of adverse events. This one-size-fits-all approach can result in both under- and over-utilization of drugs, impacting patient health and increasing costs for clinics.
Solution
nnDosis offers a cloud-based clinical decision support platform that leverages artificial intelligence and control algorithms to personalize drug dosing for patients with chronic conditions. Their Strategic Anemia Advisor (SAA) analyzes individual patient responses to medication and generates precise dosing recommendations to maintain patients within a specified therapeutic range. By optimizing drug utilization, SAA helps clinicians achieve equivalent or improved patient outcomes while reducing drug exposure and minimizing the risk of adverse events. The platform is currently focused on personalizing drug dosing for erythropoiesis-stimulating agents (ESAs) used in dialysis patients with chronic anemia, with plans to expand to other chronic disease areas.
Target Audience
The primary target audience includes nephrologists, dialysis clinics, and hospitals seeking to optimize drug dosing for chronic anemia and improve patient outcomes while reducing costs.
Features
- AI-powered engine that analyzes patient-specific responses to medication
- Personalized dosing recommendations to keep patients within a specified therapeutic range
- Cloud-based platform accessible to clinicians
- Integration with existing clinical workflows
- Proven track record of reducing drug utilization while maintaining patient outcomes, with demonstrated 40% reduction in Epoetin Beta utilization
- Pricing model based on a share of realized savings, aligning incentives with clinics
- Future modules planned for Mineral and Bone Disorder (MBD) management and IV Iron dosing